Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.66 |
| ▸ | GAA | P10253 | 1/20 | 0.66 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.66 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.66 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.66 |
| ▸ | NPC1 | O15118 | 3/20 | 0.65 |
| ▸ | RAB9A | P51151 | 3/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.63 |
| ▸ | PPARA | Q07869 | 1/20 | 0.63 |
| ▸ | TSHR | P16473 | 1/20 | 0.63 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.63 |
| ▸ | CHRNA5 | P30532 | 1/20 | 0.63 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | TP53 | P04637 | 3/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12369729 | 0.84 | PPARA (0.72) | CYP1A2CYP3A4GAACYP2D6CYP2C9 | |
| SCHEMBL13401008 | 0.83 | KDM4E (0.67) | CYP1A2CYP3A4GAACYP2D6CYP2C9 | |
| SCHEMBL12396054 | 0.81 | PPARA (0.82) | CYP1A2CYP3A4GAACYP2D6CYP2C9 | |
| SCHEMBL655414 | 0.81 | NOTUM (0.68) | CYP1A2CYP2D6CYP2C19NPC1RAB9A | |
| SCHEMBL19080613 | 0.80 | L3MBTL1 (0.65) | CYP1A2CYP3A4GAACYP2D6CYP2C9 | |
| SCHEMBL4288756 | 0.80 | S1PR1 (0.61) | NPC1RAB9ATSHRSMN1; SMN2LMNA | |
| SCHEMBL12611723 | 0.80 | CYP1A2 (0.42) | CYP1A2CYP3A4GAACYP2D6CYP2C9 | |
| SCHEMBL12617891 | 0.78 | NOTUM (0.64) | CYP1A2CYP2D6CYP2C19NPC1RAB9A | |
| SCHEMBL1422890 | 0.78 | CHRNB2 (1.00) | NPC1RAB9APPARATSHRCHRNB2 | |
| SCHEMBL4107632 | 0.77 | RAB9A (0.76) | NPC1RAB9AMAPK1TSHRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100016307-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-01-21 | — | — | US | claimed |
| US-10662180-B2 | Proteasome chymotrypsin-like inhibition using PI-1833 analogs | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2020-05-26 | — | — | US | disclosed |
| US-10662180-B2 | Proteasome chymotrypsin-like inhibition using PI-1833 analogs | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2020-05-26 | — | — | US | disclosed |
| US-20180215742-A1 | PROTEASOME CHYMOTRYPSIN-LIKE INHIBITION USING PI-1833 ANALOGS | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2018-08-02 | — | — | US | disclosed |
| US-20180215742-A1 | PROTEASOME CHYMOTRYPSIN-LIKE INHIBITION USING PI-1833 ANALOGS | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2018-08-02 | — | — | US | disclosed |
| US-20180215742-A1 | PROTEASOME CHYMOTRYPSIN-LIKE INHIBITION USING PI-1833 ANALOGS | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2018-08-02 | — | — | US | disclosed |
| US-9884832-B2 | Inhibitors targeting drug-resistant influenza A | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2018-02-06 | — | — | US | disclosed |
| US-9878999-B2 | Proteasome chymotrypsin-like inhibition using PI-1833 analogs | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2018-01-30 | — | — | US | disclosed |
| US-9878999-B2 | Proteasome chymotrypsin-like inhibition using PI-1833 analogs | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2018-01-30 | — | — | US | disclosed |
| US-9878999-B2 | Proteasome chymotrypsin-like inhibition using PI-1833 analogs | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2018-01-30 | — | — | US | disclosed |
| US-20070078154-A1 | Quinoline potassium channel inhibitors | MERCK SHARP & DOHME CORP. | 2007-04-05 | — | — | US | disclosed |
| US-20070043042-A1 | Such as 2-(Allyloxy)-4-(3-fluorophenyl)-6-methoxyquinoline-3-carbonitrile; for treating cardiac arrhthymias | MERCK & CO., INC. (US) | 2007-02-22 | — | — | US | disclosed |
| WO-2007015809-A2 | HIV REVERSE TRANSCRIPTASE INHIBITORS | MERCK & CO., INC. (US) | 2007-02-08 | — | — | WO | disclosed |
| US-20070021442-A1 | HIV reverse transcriptase inhibitors | MERCK SHARP & DOHME CORP. | 2007-01-25 | — | — | US | disclosed |
| EP-1667973-A2 | QUINOLINE POTASSIUM CHANNEL INHIBITORS | Merck & Co., Inc. (US) | 2006-06-14 | — | — | EP | disclosed |
| EP-1667683-A2 | QUINOLINE POTASSIUM CHANNEL INHIBITORS | Merck & Co., Inc. (US) | 2006-06-14 | — | — | EP | disclosed |
| WO-2005030129-A2 | QUINOLINE POTASSIUM CHANNEL INHIBITORS | MERCK & CO., INC. (US) | 2005-04-07 | — | — | WO | disclosed |
| WO-2005030792-A2 | QUINOLINE POTASSIUM CHANNEL INHIBITORS | MERCK & CO., INC. (US) | 2005-04-07 | — | — | WO | disclosed |
| US-RE32154-E | FROM BENZO-THIETANE-2-SPIRO-2'(1,3'-DIZACCYCLOALKANE AND ALKYL HALIDE | BASF AKTIENGESELLSCHAFT (DE) | 1986-05-20 | — | — | US | disclosed |
| US-4122263-A | REACTING A BENZOTHIETANE-2-SPIRO-2'(1',3'-DIAZACYCLOALKANE) WITH AN ALKYL HALIDE | BASF AKTIENGESELLSCHAFT (DE) | 1978-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078154-A1 | Quinoline potassium channel inhibitors | KCNQ2, KCNQ1, KCNJ2 | CYP1A2 1227/4885CYP3A4 945/4885GAA 3264/4885 |
| US-10662180-B2 | Proteasome chymotrypsin-like inhibition using PI-1833 analogs | PSMB3, PSME3, PSMD3 | CYP1A2 2569/4885CYP3A4 1630/4885GAA 771/4885 |
| US-20070021442-A1 | HIV reverse transcriptase inhibitors | POLRMT, RNGTT, POLR2E | CYP1A2 1057/4885CYP3A4 862/4885GAA 279/4885 |
| US-20180215742-A1 | PROTEASOME CHYMOTRYPSIN-LIKE INHIBITION USING PI-1833 ANALOGS | PSMB3, PSME3, PSMD3 | CYP1A2 2569/4885CYP3A4 1630/4885GAA 771/4885 |
| US-20100016307-A1 | NOVEL COMPOUNDS | MET, HGF, HGFAC | CYP1A2 861/4885CYP3A4 1805/4885GAA 1163/4885 |
| US-20070043042-A1 | Such as 2-(Allyloxy)-4-(3-fluorophenyl)-6-methoxyquinoline-3-carbonitrile; for treating cardiac arrhthymias | KCNH2, KCNJ2, KCNQ1 | CYP1A2 321/4885CYP3A4 348/4885GAA 4176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.